SCHEMBL7175199

SCHEMBL7175199

COc1cccc(Cl)c1C(=O)Pc1c(OCC(C)C)cc(OCC(C)C)cc1OCC(C)C.[LiH]

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FOS P01100 2/20 0.37
JUN P05412 2/20 0.37
PTGER1 P34995 3/20 0.36
HTR1D P28221 2/20 0.35
PDE4B Q07343 1/20 0.35
ITGB1 P05556 1/20 0.35
ITGA4 P13612 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
CASR P41180 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
MAPT P10636 1/20 0.34
SIRT2 Q8IXJ6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181868 0.94 FOS (0.40) FOSJUNPTGER1HTR1DMAPT
SCHEMBL7189328 0.93 FOS (0.39) FOSJUNPDE4BCA12CA1
SCHEMBL7189068 0.89 PTGER1 (0.38) FOSJUNPTGER1HTR1DMAPT
SCHEMBL7188974 0.87 FOS (0.38) FOSJUNMAOAMAOBCASR
SCHEMBL7179902 0.87 HTT (0.39) CA12CA1CA2CA7CA9
SCHEMBL7189482 0.85 SMN1; SMN2 (0.45) CA12CA1CA2CA7CA9
Lithium SCHEMBL7188985 0.85 SLC16A3 (0.36) FOSJUNMAOAMAOBCASR
SCHEMBL7190315 0.84 SMN1; SMN2 (0.39) FOSJUNITGB1ITGA4MAOA
SCHEMBL7174547 0.84 ALDH1A1 (0.41) CASRCA2
SCHEMBL7185228 0.83 USP2 (0.38) FOSJUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 FOS 2702/4885JUN 4136/4885PTGER1 3015/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 FOS 2549/4885JUN 3781/4885PTGER1 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.